325 related articles for article (PubMed ID: 37168382)
1. PARP inhibitors in metastatic prostate cancer.
Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
[TBL] [Abstract][Full Text] [Related]
2. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
[TBL] [Abstract][Full Text] [Related]
3. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
4. Development of PARP inhibitors in advanced prostate cancer.
Bourlon MT; Valdez P; Castro E
Ther Adv Med Oncol; 2024; 16():17588359231221337. PubMed ID: 38205078
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
[TBL] [Abstract][Full Text] [Related]
6. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E; Antonarakis ES
Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
9. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
10. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.
LeVee A; Lin CY; Posadas E; Figlin R; Bhowmick NA; Di Vizio D; Ellis L; Rosser CJ; Freeman MR; Theodorescu D; Freedland SJ; Gong J
Onco Targets Ther; 2021; 14():4819-4832. PubMed ID: 34552338
[TBL] [Abstract][Full Text] [Related]
12. Research progress on the treatment of advanced prostate cancer with Olaparib.
Su YX; Yu CF; Xue P; Li LL; Xiao KM; Chu XL; Zhu SJ
Neoplasma; 2021 Nov; 68(6):1132-1138. PubMed ID: 34779643
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Jang A; Sartor O; Barata PC; Paller CJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320
[TBL] [Abstract][Full Text] [Related]
14. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Faraoni I; Graziani G
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Bieńkowski M; Tomasik B; Braun M; Jassem J
Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Somatic or Germline Homologous Recombination Repair Gene Mutations: Phase II Single-Arm Trial.
Jain R; Kumar A; Sharma A; Sahoo RK; Sharma A; Seth A; Nayak B; Shamim SA; Kaushal S; Kp H; Das CJ; Batra A
JMIR Res Protoc; 2024 Apr; 13():e54086. PubMed ID: 38453159
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in prostate cancers, is it time for combinations?
Teyssonneau D; Dariane C; Barret E; Beauval JB; Brureau L; Fiard G; Fromont G; Créhange G; Gauthé M; Ruffion A; Renard-Penna R; Mathieu R; Sargos P; Rouprêt M; Ploussard G; Roubaud G
Ther Adv Med Oncol; 2024; 16():17588359241242959. PubMed ID: 38827177
[TBL] [Abstract][Full Text] [Related]
19. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
20. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS; Camacho CV; Kraus WL
Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
